OraSure OraQuick
This article was originally published in The Gray Sheet
Executive Summary
Rapid HIV-1 antibody test is deemed "approvable" by FDA pending resolution of "specific validation and control issues" detected during a recent agency inspection of the firm's manufacturing facilities, OraSure announces May 13. The test can detect HIV-1 antibodies in whole blood via a finger stick within 20 minutes (1"The Gray Sheet" May 6, 2002, p. 42). A market launch is slated for the second half of the year...
You may also be interested in...
OraSure License/Marketing Pact With Abbott To Aid OraQuick HIV Test Launch
OraSure Technologies' license of non-exclusive rights to certain test strip technology patents from Abbott appears to clear the way for a U.S. launch of OraSure's OraQuick rapid HIV-1 test, pending FDA approval
OraSure OraQuick HIV Blood Test Launch Expected In Latter Half Of 2002
OraSure anticipates FDA approval of its OraQuick fingerstick whole blood rapid HIV-1 test by mid-May
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.